Time required for successful intubation · neonates (0 to 28 days of age) who needed tracheal intubation
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of intubation attempts · neonates (0 to 28 days of age) who needed tracheal intubation
1 finding from 1 review
no estimate extracted
Studies not reported
Low
First‐attempt success rate · neonates (0 to 28 days of age) who needed tracheal intubation
Videolaryngoscopy may leads to higher success rate at first attempt compared with conventional direct laryngoscopy (low certainty).
1 finding from 1 review
RR 1.24 [1.13, 1.37]
Studies not reported
Low
Non‐airway‐related adverse effects: desaturation or bradycardia episodes, or both · neonates (0 to 28 days of age) who needed tracheal intubation
It is very uncertain whether videolaryngoscopy changes non‐airway‐related adverse effects: desaturation or bradycardia… compared with conventional direct laryngoscopy (very low certainty).
1 finding from 1 review
RR 0.94 [0.38, 2.3]
Studies not reported
Very low
Non‐airway‐related adverse effects: lowest saturations during intubation · neonates (0 to 28 days of age) who needed tracheal intubation
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Airway‐related adverse effects: airway trauma · neonates (0 to 28 days of age) who needed tracheal intubation
Videolaryngoscopy probably leads to lower airway‐related adverse effects: airway trauma compared with conventional direct laryngoscopy (moderate certainty).
1 finding from 1 review
RR 0.21 [0.05, 0.79]
Studies not reported
Moderate
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review